Cancer Family
Digestive System Neuroendocrine Neoplasm
CI-CAN-00000164Explore in graph →
Non-malignant76 active trials2 evidence items
- NCIt
- C27721
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000164Explore in graph →
Clinical trials
295 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 6 | Changhai HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05987176 | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases(NELMAS) | terminated | Phase 2 | 1 | Imperial College LondonOTHER | 1 | Jan 14, 2026 |
| NCT04579679 | Open-Label Surufatinib in European Patients With NET | terminated | Phase 2 | 78 | HutchmedINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | terminated | Phase 2 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05568017 | Neoadjuvant PRRT With Y-90-DOTATOC in pNET(NeoNet) | terminated | Phase 2 | 11 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00466856 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | terminated | Phase 2 | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 11, 2026source: clinicaltrials